Sanjay Popat

Research interests

Publications

• Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2024 · https://doi.org/10.1056/nejmoa2302299

• RETRACTED ARTICLE: Antibodies against endogenous retroviruses promote lung cancer immunotherapy

  Nature · 2023 · https://doi.org/10.1038/s41586-023-05771-9

• Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2306441

• ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

  Annals of Oncology · 2022 · https://doi.org/10.1016/j.annonc.2022.02.003

• ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group

  Annals of Oncology · 2022 · https://doi.org/10.1016/j.annonc.2022.05.520

• Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

  Journal of Thoracic Oncology · 2021 · https://doi.org/10.1016/j.jtho.2021.07.035

• First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

  The Lancet · 2021 · https://doi.org/10.1016/s0140-6736(20)32714-8

• Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

  Journal of Clinical Oncology · 2020 · https://doi.org/10.1200/jco.20.00505

• Correction to: “Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”

  Annals of Oncology · 2019 · https://doi.org/10.1093/annonc/mdy474

• Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

  Annals of Oncology · 2019 · https://doi.org/10.1093/annonc/mdz167

• Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy275

• Brigatinib versus Crizotinib in ALK -Positive Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1810171

• Novel insights into mesothelioma biology and implications for therapy

  Nature reviews. Cancer · 2017 · https://doi.org/10.1038/nrc.2017.42

• Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial

  The Lancet Respiratory Medicine · 2017 · https://doi.org/10.1016/s2213-2600(17)30129-7

• High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial

  Cancer Discovery · 2016 · https://doi.org/10.1158/2159-8290.cd-15-1246

• First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases

  Journal of Thoracic Oncology · 2016 · https://doi.org/10.1016/j.jtho.2015.11.014

• Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2016 · https://doi.org/10.1093/annonc/mdw326

• Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

  The Lancet Oncology · 2015 · https://doi.org/10.1016/s1470-2045(14)71173-8

• Systematic Review of Microsatellite Instability and Colorectal Cancer Prognosis

  Journal of Clinical Oncology · 2005 · https://doi.org/10.1200/jco.2005.01.086

• Thymidylate Synthase Expression and Prognosis in Colorectal Cancer: A Systematic Review and Meta-Analysis

  Journal of Clinical Oncology · 2004 · https://doi.org/10.1200/jco.2004.05.064

Current projects

No projects listed.